Oncotarget · 2015 · 44 citations · 57 references
MedicineOncologyCarcinogenesisCell SignalingMetastasisOncogenic Signaling PathwaysSignal Transduction In CancerVitamin D MetabolismRon Receptor SignalingTumor Cell ProliferationVitamin D Receptor SignalingVitamin D Receptors
// Abby L. Johnson 1,2 , Glendon M. Zinser 1,2 and Susan E. Waltz 2,3 1 Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio, USA 2 Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA 3 Department of Research Service, Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, USA Correspondence to: Susan E. Waltz, email: // Keywords : vitamin D3 receptor, ron, β-catenin, breast cancer Received : January 28, 2015 Accepted : April 22, 2015 Published : May 10, 2015 Abstract The Ron receptor is upregulated in human breast cancers and correlates with enhanced metastasis and reduced patient survival. Ron overexpression drives mammary tumorigenesis through direct β-catenin activation and augmented tumor cell proliferation, migration and invasion. Ron and β-catenin are also coordinately elevated in breast cancers. The vitamin D receptor (VDR) antagonizes β-catenin signaling. Herein, we examined mammary tumor onset and progression using a Ron-driven murine model of breast tumorigenesis crossed with VDR deficient mice. VDR ablation accelerated mammary tumor onset and led to tumors that exhibited a desmoplastic phenotype and enhanced metastases. Tumor levels of active β-catenin were markedly increased in the absence of VDR. In vitro , VDR activation in breast cancer cells reduced β-catenin activation and transcriptional activity leading to elevated expression of the extracellular Wnt inhibitor dickkopf-related protein 1, and a reduction in the interaction of β-catenin with the cyclin D1 promoter. Expression of a stabilized form or β-catenin ablated the protective effects of VDR activation.Collectively, these studies delineate a protective role for VDR signaling in Ron-induced mammary tumorigenesis through disruption of β-catenin activation.
57
Cynthia Yost, Matthew P. Torres, Jim Miller et al. · Genes & Development · 1996 · 1.2K citations · Full text
Héctor G. Pálmer, José Manuel González‐Sancho, Jesús Espada et al. · The Journal of Cell Biology · 2001 · 801 citations · Full text
Medicine, Oncology, Pharmacology +16